New hope for older leukemia patients: targeted combo shows promise
NCT ID NCT06456463
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times
Summary
This study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission. The trial involves about 83 participants and will first find the best dose of tagraxofusp, then test that dose in two groups based on genetic markers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AdventHealth Cancer Institute
Orlando, Florida, 32804, United States
-
Austin Hospital
Heidelberg, Victoria, 3084, Australia
-
Baylor Scott & White Health
Dallas, Texas, 75246, United States
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Box Hill Hospital
Box Hill, Victoria, 3128, Australia
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Concord Repatriation General Hospital
Concord, New South Wales, 2139, Australia
-
Dana Farber Cancer Institute (DFCI)
Boston, Massachusetts, 02114, United States
-
Henry Ford Health System Brigitte Harris Cancer Pavillion
Detroit, Michigan, 48202, United States
-
John Theurer Cancer Center - Hackensack Meridian Health
Hackensack, New Jersey, 07601, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Monash Medical Centre
Clayton, Victoria, 3168, Australia
-
NYU Langone Health
New York, New York, 10016, United States
-
North Shore University Hospital
Manhasset, New York, 11030, United States
-
Novant Health Derrick L Davis Cancer Center
Winston-Salem, North Carolina, 27103, United States
-
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14203, United States
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
-
Royal Perth Hospital
Perth, Western Australia, 6000, Australia
-
Rutgers Cancer Institute
New Brunswick, New Jersey, 08901, United States
-
Sarah Cannon, the Cancer Institute of HCA Healthcare
Nashville, Tennessee, 37203, United States
-
St. Vincents Hospital
Fitzroy, Victoria, 3065, Australia
-
Stanford Health Care
Stanford, California, 94305, United States
-
Sydney Kimmel (Thomas Jefferson University)
Philadelphia, Pennsylvania, 19107, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Townsville Hospital
Douglas, Queensland, 4814, Australia
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Washington University - Siteman Cancer Center
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?